Phosphoinositide 3-kinase (PI3K) activity is stimulated by diverse oncogenes and growth
factor receptors, and elevated PI3K signaling is considered a hallmark of cancer. Many PI3K …

Phosphatidylinositol 3-kinase (PI3K), protein kinase B (PKB/AKT) and mechanistic target of
rapamycin (mTOR)(PAM) pathways play important roles in breast tumorigenesis and confer …

Background In the randomised, parallel assignment, open-label, phase 3 TH3RESA study,
progression-free survival was significantly longer with trastuzumab emtansine versus …

The central role of phosphoinositide 3-kinase (PI3K) activation in tumour cell biology has
prompted a sizeable effort to target PI3K and/or downstream kinases such as AKT and …

The PI3K pathway is mutated and aberrantly activated in many cancers and plays a central
role in tumor cell proliferation and survival, making it a rational therapeutic target. Until …

PARP inhibitors are active in tumors with defects in DNA homologous recombination (HR)
due to BRCA1/2 mutations. The phosphoinositide 3-kinase (PI3K) signaling pathway …

Activation of the phosphoinositide 3 kinase (PI3K)/Akt/mammalian target of rapamycin
(mTOR) pathway is common in breast cancer. There is preclinical data to support inhibition …

Background Breast cancer is characterised by genomic alterations. We did a multicentre
molecular screening study to identify abnormalities in individual patients with the aim of …

Background Most targeted anticancer therapies, as well as cytotoxic and radiation therapies,
are encumbered by the development of secondary resistance by cancer cells. Resistance is …

Human epidermal growth factor receptor (HER) 2 (HER2) is overexpressed in 20–30% of
breast cancers. HER2 is a preferred target for treating HER2-positive breast cancer …